COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain
| العنوان: | COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain |
|---|---|
| المؤلفون: | Marian Goicoechea, Antonia Mijaylova, Manuel Rengel, Eduardo Verde, Adriana Acosta, Alberto Tejedor, David Arroyo, Arturo Bascuñana, Javier Carbayo, Ana Pérez de José, Daniel Barraca, José Luño, Ángela González Rojas, Ana María García Prieto, Soraya Abad, Andrés Delgado, Nicolás Macías, F. Anaya, Luis Alberto Sánchez Cámara, Diego Barbieri, María Luisa Rodríguez Ferrero, Alejandra Muñoz de Morales, Patrocinio Rodríguez Benítez, Rosa Melero, Almudena Vega, Ursula Verdalles, Inés Aragoncillo |
| المصدر: | Kidney International |
| بيانات النشر: | Elsevier BV, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, 0301 basic medicine, medicine.medical_treatment, 030232 urology & nephrology, Azithromycin, Lopinavir, 0302 clinical medicine, Oxygen therapy, Hospital Mortality, Aged, 80 and over, education.field_of_study, Clinical course, Middle Aged, Prognosis, Anti-Bacterial Agents, Drug Combinations, Nephrology, Hemodialysis, Female, Coronavirus Infections, Hydroxychloroquine, Adult, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Population, Article, Antimalarials, 03 medical and health sciences, Renal Dialysis, Internal medicine, medicine, Humans, education, Pandemics, Dialysis, Aged, Retrospective Studies, Ritonavir, SARS-CoV-2, business.industry, COVID-19, Retrospective cohort study, medicine.disease, mortality, Coronavirus, Pneumonia, 030104 developmental biology, Spain, Kidney Failure, Chronic, business |
| الوصف: | SARS-CoV-2-pneumonia emerged in Wuhan, China in December 2019. Unfortunately, there is lack of evidence about the optimal management of novel coronavirus disease 2019 (COVID-19), even less in patients on maintenance hemodialysis (MHD) therapy than in the general population. In this retrospective observational single-center study we analyzed the clinical course and outcomes of all MHD patients hospitalized with COVID-19 from March 12th to April 10th, 2020 as confirmed by real time polymerase chain reaction. Baseline features, clinical course, laboratory data, and different therapies were compared between survivors and non-survivors to identify risk factors associated with mortality. Among the 36 patients, 11 (30.5%) died and 7 could be discharged within the observation period. Clinical and radiological evolution during the first week of admission were predictive of mortality. Among the 36 patients, 18 had worsening of their clinical status, as defined by severe hypoxia with oxygen therapy requirements greater than 4 Liters/minute and radiological worsening. Significantly 11 out of those 18 patients (61.1%) died. None of the classical cardiovascular risk factors in the general population were associated with higher mortality. However, a longer time on hemodialysis (hazard ratio 1.008(95% confidence interval 1.001-1.015) per year), increased LDH levels (1.006(1.001-1.011), and lower lymphocyte count (0.996 (0.992-1.000) one week after clinical onset were all significantly associated with higher mortality risk. Thus, the mortality among hospitalized hemodialysis patients diagnosed with COVID-19 is high. Lymphopenia and increased LDH levels were associated with poor prognosis. Graphical abstract |
| تدمد: | 0085-2538 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf6498f836aed5e1004672420f958996 https://doi.org/10.1016/j.kint.2020.04.031 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....cf6498f836aed5e1004672420f958996 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00852538 |
|---|